Determinants of HIV-1 broadly neutralizing antibody induction
暂无分享,去创建一个
A. Trkola | J. Fellay | J. Weber | K. Metzner | M. Egger | H. Günthard | R. Weber | M. Battegay | H. Furrer | P. Vernazza | E. Bernasconi | S. Yerly | T. Klimkait | G. Pantaleo | B. Ledergerber | M. Cavassini | C. Marzolini | P. Schmid | A. Ciuffi | H. Kuster | J. Böni | R. Kouyos | A. Calmy | D. Nicca | G. Wandeler | D. Braun | J. Fehr | A. Rauch | B. Hasse | L. Elzi | N. Hozé | L. Kaiser | R. Regoes | O. Keiser | H. Hirsch | H. Bucher | C. Kadelka | V. Aubert | A. Scherrer | I. Hösli | R. Speck | G. Martinetti | P. Rusert | Carsten Magnus | C. Rudin | M. Huber | H. Kovari | P. Tarr | C. Thorball | P. Paioni | C. Kahlert | C. Fux | D. Haerry | N. Müller | M. Hoffmann | M. Stöckle | B. M. de Tejada | Hanna Ebner | M. Schanz | T. Uhr | V. Cippà | Heiner C Angela Günther Matthias Luigia Jan Hansjakob Chr Bucher Ciuffi Dollenmaier Egger Elzi Fehr | G. Dollenmaier | N. Müller | Heiner C Angela Günther Matthias Luigia Jan Hansjakob Chr Bucher Ciuffi Dollenmaier Egger Elzi Fehr
[1] Camille Roth,et al. Natural Scales in Geographical Patterns , 2017, Scientific Reports.
[2] Nico Pfeifer,et al. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption , 2016, Nature.
[3] Ben Murrell,et al. Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort , 2016, PLoS pathogens.
[4] J. Mascola,et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection , 2015, Science Translational Medicine.
[5] Lynn Morris,et al. Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies , 2015, Nature Medicine.
[6] Alan S. Perelson,et al. Competitive exclusion by autologous antibodies can prevent broad HIV-1 antibodies from arising , 2015, Proceedings of the National Academy of Sciences.
[7] L. Held,et al. Assessing the Paradox Between Transmitted and Acquired HIV Type 1 Drug Resistance Mutations in the Swiss HIV Cohort Study From 1998 to 2012. , 2015, The Journal of infectious diseases.
[8] R. McClelland,et al. The Broad Neutralizing Antibody Responses after HIV-1 Superinfection Are Not Dominated by Antibodies Directed to Epitopes Common in Single Infection , 2015, PLoS pathogens.
[9] Hyejin Yoon,et al. CATNAP: a tool to compile, analyze and tally neutralizing antibody panels , 2015, Nucleic Acids Res..
[10] John R Mascola,et al. Antibody responses to envelope glycoproteins in HIV-1 infection , 2015, Nature Immunology.
[11] Michael S. Seaman,et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117 , 2015, Nature.
[12] L. Morris,et al. Virological features associated with the development of broadly neutralizing antibodies to HIV-1. , 2015, Trends in microbiology.
[13] I. Wilson,et al. Insights into the trimeric HIV-1 envelope glycoprotein structure. , 2015, Trends in biochemical sciences.
[14] Jerome H. Kim,et al. Impact of Clade, Geography, and Age of the Epidemic on HIV-1 Neutralization by Antibodies , 2014, Journal of Virology.
[15] J. Overbaugh,et al. Early development of broad neutralizing antibodies in HIV-1 infected infants , 2014, Nature Medicine.
[16] L. Morris,et al. Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection , 2014, Current opinion in HIV and AIDS.
[17] Chaim A. Schramm,et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies , 2014, Nature.
[18] B. Korber,et al. Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection , 2014, AIDS.
[19] B. Haynes,et al. Immune System Regulation in the Induction of Broadly Neutralizing HIV-1 Antibodies , 2013, Vaccines.
[20] Alessandro Sette,et al. Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. , 2013, Immunity.
[21] L. Morris,et al. Viral Escape from HIV-1 Neutralizing Antibodies Drives Increased Plasma Neutralization Breadth through Sequential Recognition of Multiple Epitopes and Immunotypes , 2013, PLoS pathogens.
[22] Florian Klein,et al. Antibodies in HIV-1 Vaccine Development and Therapy , 2013, Science.
[23] L. Morris,et al. Evaluation of sequence ambiguities of the HIV-1 pol gene as a method to identify recent HIV-1 infection in transmitted drug resistance surveys. , 2013, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.
[24] Young Do Kwon,et al. Residue-Level Prediction of HIV-1 Antibody Epitopes Based on Neutralization of Diverse Viral Strains , 2013, Journal of Virology.
[25] B. Haynes,et al. HIV‐1 neutralizing antibodies: understanding nature's pathways , 2013, Immunological reviews.
[26] Tongqing Zhou,et al. Delineating Antibody Recognition in Polyclonal Sera from Patterns of HIV-1 Isolate Neutralization , 2013, Science.
[27] Tongqing Zhou,et al. Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization , 2013, Cell.
[28] Chaim A. Schramm,et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus , 2013, Nature.
[29] Lynn Morris,et al. Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escape , 2012, Nature Medicine.
[30] Adam Godzik,et al. A Blueprint for HIV Vaccine Discovery. , 2012, Cell host & microbe.
[31] J. Mascola,et al. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. , 2012, Immunity.
[32] S. Aris-Brosou,et al. Genetic diversity as a marker for timing infection in HIV-infected patients: evaluation of a 6-month window and comparison with BED. , 2012, The Journal of infectious diseases.
[33] K. Metzner,et al. Characterization of human immunodeficiency virus type 1 (HIV-1) diversity and tropism in 145 patients with primary HIV-1 infection. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[34] H. Schuitemaker,et al. Longitudinal Analysis of Early HIV-1-Specific Neutralizing Activity in an Elite Neutralizer and in Five Patients Who Developed Cross-Reactive Neutralizing Activity , 2011, Journal of Virology.
[35] H. Günthard,et al. The role of migration and domestic transmission in the spread of HIV-1 non-B subtypes in Switzerland. , 2011, The Journal of infectious diseases.
[36] Mario Roederer,et al. Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing , 2011, Science.
[37] Huldrych F. Günthard,et al. Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies , 2011, The Journal of experimental medicine.
[38] L. Morris,et al. The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4+ T Cell Decline and High Viral Load during Acute Infection , 2011, Journal of Virology.
[39] Beda Joos,et al. Ambiguous Nucleotide Calls From Population-based Sequencing of HIV-1 are a Marker for Viral Diversity and the Age of Infection , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[40] M. Altfeld,et al. Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1 , 2011, PLoS pathogens.
[41] Amalio Telenti,et al. Cohort profile: the Swiss HIV Cohort study. , 2010, International journal of epidemiology.
[42] Dennis R. Burton,et al. A Limited Number of Antibody Specificities Mediate Broad and Potent Serum Neutralization in Selected HIV-1 Infected Individuals , 2010, PLoS pathogens.
[43] H. Günthard,et al. HIV-1 transmission after cessation of early antiretroviral therapy among men having sex with men , 2010, AIDS.
[44] Matthias Cavassini,et al. Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland. , 2010, The Journal of infectious diseases.
[45] Richard T. Wyatt,et al. Breadth of Human Immunodeficiency Virus-Specific Neutralizing Activity in Sera: Clustering Analysis and Association with Clinical Variables , 2009, Journal of Virology.
[46] J. Baeten,et al. Breadth of Neutralizing Antibody Response to Human Immunodeficiency Virus Type 1 Is Affected by Factors Early in Infection but Does Not Influence Disease Progression , 2009, Journal of Virology.
[47] Terri Wrin,et al. Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm , 2009, Journal of Virology.
[48] Xuesong Yu,et al. Factors Associated with the Development of Cross-Reactive Neutralizing Antibodies during Human Immunodeficiency Virus Type 1 Infection , 2008, Journal of Virology.
[49] Patrick Taffé,et al. A joint back calculation model for the imputation of the date of HIV infection in a prevalent cohort , 2008, Statistics in medicine.
[50] Lynn Morris,et al. Profiling the Specificity of Neutralizing Antibodies in a Large Panel of Plasmas from Patients Chronically Infected with Human Immunodeficiency Virus Type 1 Subtypes B and C , 2008, Journal of Virology.
[51] Douglas D. Richman,et al. Dissecting the Neutralizing Antibody Specificities of Broadly Neutralizing Sera from Human Immunodeficiency Virus Type 1-Infected Donors , 2007, Journal of Virology.
[52] A. Trkola,et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies , 2005, Nature Medicine.
[53] S. Self,et al. Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines. , 2004, The Journal of infectious diseases.
[54] M. Hersberger,et al. Deliberate removal of T cell help improves virus-neutralizing antibody production , 2004, Nature Immunology.
[55] Martin A. Nowak,et al. Antibody neutralization and escape by HIV-1 , 2003, Nature.
[56] J. Margolick,et al. Consistent Viral Evolutionary Changes Associated with the Progression of Human Immunodeficiency Virus Type 1 Infection , 1999, Journal of Virology.
[57] Roger Detels,et al. Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection , 1997, Annals of Internal Medicine.
[58] John W. Ward,et al. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. , 1993, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[59] William M. Rand,et al. Objective Criteria for the Evaluation of Clustering Methods , 1971 .